Ireland
--:--IST
Latest
Clinical Trials in Turkey / NCT07642531
Starting soon Not applicable

A Modular Cloud Platform For Fertility Preservation

NCT07642531 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-09-02
Last updated
2026-06-12

Condition(s) studied

Fertility PreservationGynecologic Cancers

Investigational drug(s) / intervention(s)

Developing a Modular Cloud-Based Platform to guide decision-making in fertility preservation

Developing a Modular Cloud-Based Platform to guide decision-making in fertility preservation: In this study, a modular cloud-based platform will be developed to raise awareness about fertility preservation.

Study summary

The research was designed as a randomized controlled study to determine the effectiveness of a modular cloud-based training platform in increasing awareness of fertility preservation.

The study aims to develop a free, modular, cloud-based, sustainable digital platform to increase fertility awareness. The platform will provide basic information on fertility preservation methods in plain language to support informed decisions. Content will be based on European Society of Human Reproduction and Embryology (ESHRE) , International Federation of Gynaecology and Obstetrics (FIGO) and Asian Society of Gynecologic Oncology (ASCO) guidelines. The study targets not only cancer patients but also women requesting fertility preservation for medical or social reasons.

In the first stage, the platform will be designed with the ADDIE instructional design model (Analysis, Design, Development, Implementation, Evaluation) and content created per international guidelines. In the second stage, the prototype will be pilot-tested and revised. In the third stage, effectiveness will be tested through a randomized controlled trial. Educational modules will be provided to the intervention group, while the control group will receive brochures. The study will include women aged 18-45 with early-stage gynecological cancer (cervix, ovary, tube, endometrium) at Prof. Dr. Cemil Tascioglu City Hospital, untreated. Participants must have Turkish literacy and internet access. Sample size, calculated with G\*Power, is 140 total (70 per group).

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Women of reproductive age between the ages of 18 and 45, * Diagnosed with early stage cervical cancer, ovarian cancer, tubal cancer and endometrial cancer and whose treatment has not started, * Those who have a smartphone and can use the platform, * Volunteering and giving informed consent, * Turkish literate, * Individuals who do not report mental problems * Do not have children, * Marital status is married or single. Exclusion Criteria: * Neurological disease (e.g., stroke, multiple sclerosis) or cognitive impairment, * Advanced-stage gynecologic cancers, * Failure to complete the follow-up period, * Initiation of oncologic treatment during the study period, * Non-completion or incomplete completion of the data collection instruments, * Non-use of the platform among participants allocated to the intervention group, * History of prior cancer treatment.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Biruni University Istanbul Zeytinburnu

More Biruni University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07642531 on ClinicalTrials.gov ↗ ← All trials in Turkey